Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annovis Bio, Inc. (ANVS) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Annovis is a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, and its filings offer detailed insight into its clinical programs, financial condition, capital structure, and governance.
Through periodic reports and current reports on Form 8‑K, Annovis discloses material events such as registered direct offerings of common stock and pre‑funded warrants under its Form S‑3 shelf registration statement, the intended use of proceeds for the continued clinical development of buntanetap and general corporate purposes, and engagement terms with placement agents. Other 8‑K filings describe leadership changes, including appointments and resignations in finance roles, annual meeting voting results, and matters such as NYSE listing compliance plan acceptance.
Investors following Annovis’ late-stage clinical activities can also use SEC filings to connect financial updates with the company’s development plans. Earnings-related 8‑K filings furnish press releases that summarize research and development expenses, general and administrative costs, and net loss figures for specified reporting periods, alongside narrative corporate updates on the pivotal Phase 3 Alzheimer’s trial and other clinical milestones.
On this page, users can review real-time updates as new filings appear on EDGAR, including future annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and additional 8‑K disclosures. AI-powered tools on the platform can help summarize lengthy documents, highlight key sections on topics such as financing terms, clinical development priorities, or listing status, and make it easier to navigate complex language. For those analyzing ANVS, this filings archive is a primary source for understanding how Annovis reports its progress, risks, and obligations in connection with the development of buntanetap and its broader corporate activities.
Annovis Bio, Inc. director reported open-market purchases of the company’s common stock. On 12/08/2025, the reporting person bought 30,000 shares at $4.3398 per share and an additional 15,000 shares at $4.24 per share. After these transactions, the reporting person beneficially owned 2,574,739 shares of Annovis Bio common stock directly. An additional 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.
Annovis Bio, Inc. (ANVS) reported an amended Form 4 for a director showing multiple open-market purchases of common stock on 11/24/2025. The director bought 1,489 shares at $4.13, 9,200 shares at $3.85, 415 shares at $4.14, and 28,096 shares at $4.15. After these transactions, the director beneficially owned 2,529,739 shares directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The amendment states it was filed to correct the share totals shown in column 5 after each reported transaction, with no other changes to the previously reported trades.
A director of Annovis Bio, Inc. (ANVS) reported several open-market purchases of the company’s common stock. On 11/24/2025, the director bought blocks of Annovis Bio common shares at prices of $4.13, $3.85, $4.14, and $4.15 per share, each coded as a purchase transaction.
Following these transactions, the director beneficially owns 2,519,739 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power. The filing confirms the director’s status and that the report is filed for a single reporting person.
Annovis Bio, Inc. (ANVS) reported an insider stock purchase by a director. On 11/21/2025, the reporting person bought 10,000 shares of common stock at $3.49 per share and another 10,000 shares at $3.50 per share. After these transactions, the director beneficially owned 2,490,539 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.
Annovis Bio, Inc. director reported purchasing 15,000 shares of common stock at $2.11 per share on 11/14/2025.
After this transaction, the director beneficially owns 2,470,539 shares directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.
Annovis Bio, Inc. filed a current report stating that it has released its latest earnings information. On November 12, 2025, the company issued a press release reporting financial results for the quarter and nine months ended September 30, 2025. The press release, which contains the detailed figures and discussion of the results, is attached to the report as Exhibit 99 and incorporated by reference.
Annovis Bio (ANVS) filed its Q3 2025 10‑Q reporting continued operating losses and a going‑concern warning. The company posted a Q3 net loss of $7.3 million as research and development rose to $6.3 million with spending tied to its 6‑month Alzheimer’s trial and a Parkinson’s open‑label extension. General and administrative costs fell to $1.1 million. Cash and cash equivalents were $15.3 million, and warrant liability measured at fair value was $299,000.
Year‑to‑date, the net loss was $19.0 million, with higher interest income reflecting cash raised earlier in the year. Management concluded that existing cash is not sufficient for the period through one year after this report, indicating substantial doubt about the company’s ability to continue as a going concern, and plans to seek additional capital.
Financing activity included a February 2025 underwritten offering of 5.3 million units at $4.00 per unit (net proceeds $19.3 million) and sales under an ATM program. Subsequent to quarter‑end, the company raised $5.5 million in a registered direct offering on October 10, 2025 and $3.1 million on October 26, 2025. Shares outstanding were 20,187,904 at September 30, 2025; as of November 12, 2025, outstanding shares were 26,502,889.
Annovis Bio (ANVS) reported an insider share purchase by President & CEO and Director Maria Maccecchini. On 10/28/2025, she acquired 97,561 shares of common stock at $2.05 per share.
Following the transaction, she beneficially owns 1,212,020 shares, held directly. This filing reflects a personal share acquisition by a senior executive.
Annovis Bio (ANVS) — insider transaction. A director reported purchasing 975,610 shares of common stock at $2.05 on 10/28/2025 (Transaction Code P). Following the trade, the filer reported 2,455,539 shares held directly and 223,357 shares held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The filing notes the reporting person has voting and investment power over the trust-held shares.
Annovis Bio (ANVS) reported an insider transaction on a Form 4. Director Claudine Bruck exercised a stock option and acquired 7,142 shares of common stock at $0.14 per share on 09/10/2025 (transaction code M).
Following the transaction, her directly held common stock totaled 13,709 shares. The option exercised had been exercisable since 09/18/2016 and carried an expiration date of 09/18/2025, and the derivative position reported after the exercise was 0.